Camilla Sandberg

Chief Executive Officer presso MIRIS HOLDING AB

57 anni

Health Technology

Electronic Technology

Consumer Services

Profilo

Camilla Myhre Sandberg is currently the Chief Executive Officer at Miris Holding AB since 2016.
She is also an Independent Director at Monivent AB and NextCell Pharma AB.
Previously, she worked as the Vice President-Sales & Marketing at BioLamina AB.
Ms. Sandberg completed her undergraduate degree in 1996 and MBA in 1998 from the University of Oslo.

Posizioni attive di Camilla Sandberg

Società	Posizione	Inizio
MIRIS HOLDING AB	Chief Executive Officer	04/10/2016
NEXTCELL PHARMA AB	Director/Board Member	01/01/2017
MONIVENT AB	Director/Board Member	-

Tutte le posizioni attive di Camilla Sandberg

Precedenti posizioni note di Camilla Sandberg

Società	Posizione	Fine
BioLamina AB BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.	Sales & Marketing	-

Vedi nel dettaglio l'esperienza di Camilla Sandberg

Formazione di Camilla Sandberg

University of Oslo

Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Camilla Sandberg

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
MIRIS HOLDING AB	Electronic Technology
MONIVENT AB	Health Technology
NEXTCELL PHARMA AB	Health Technology

Aziende private	1
BioLamina AB BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden.	Health Technology